Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases. Our understanding of the pathophysiology of the disease has improved, but pharmacological treatments with proven outcomes benefits in HFpEF have proved elusive thus far. Current clinical guidelines focus on the management of comorbidities with angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and diuretics, but despite the long list of clinical trial failures, promising drugs are in Phase III trials.


  • What are the treatment drivers and goals for HFpEF?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for HFpEF?
  • What are the prevailing areas of unmet need and opportunity in HFpEF?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists for a hypothetical new HFpEF drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in August 2019

Key companies: Novartis, Eli Lilly, Boehringer Ingelheim, AstraZeneca


  • Target Product Profile (TPP) simulator based on conjoint analysis methodology.
  • Stated versus derived importance of product attributes on prescribing behavior.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet needs in HFpEF and related indications.
  • Analysis of remaining drug development opportunities.

Key drugs:ACE inhibitors, angiotensin II receptor blockers,beta blockers, calciumchannel blockers, diuretics, spironolactone, Entresto (sacubitril/valsartan)


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis Heart Failure: Preserved Ejection Fraction (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Heart Failure with Preserved Ejection Fraction
      • Key Findings: Unmet Need in Heart Failure with Preserved Ejection Fraction and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Heart Failure with Preserved Ejection Fraction Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent That Improves CV Mortality and Lowers Rate of Hospitalization in HFpEF Patients
        • Opportunity: A Novel Agent That Improves Quality-of-Life Measures and Exercise Capacity in HFpEF Patients
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Heart Failure with Preserved Ejection Fraction Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Kahkashan Resham, Ph.D

Kahkashan Resham is a senior research associate in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. Her current work is focused on writing treatment algorithm reports, key opinion leader identification, clinical trial pipeline pulls, as well as secondary research across multiple cardiovascular and metabolic indications. Prior to joining DRG, Resham obtained her doctorate in Pharmacology from National Institute of Pharmaceutical Education and Research (NIPER), Nagar, India. She completed her M. Pharm. from the NIPER Hyderabad and was awarded a gold medal for securing 1st rank in the Institute. She holds a bachelor’s degree in Pharmacy from Birla Institute of Technology, Ranchi, India. Resham has also published several peer-reviewed research articles in the area of drug metabolism, diabetes and chemotherapy-induced peripheral neuropathic pain.

Related Reports

Heart Failure | Landscape & Forecast | Disease Landscape & Forecast

Heart failure (HF) is categorized into acute or chronic, and both settings are the focus of this report. While much progress has been made in the pharmacological management of HF, it mainly...

View Details

Heart Failure | Unmet Need | Detailed, Expanded Analysis Acute Heart Failure (US/EU)

Acute heart failure (AHF) is characterized by the rapid onset or aggravation of symptoms of heart failure. The standard of care in AHF has remained largely unchanged since the 1970s, resulting in...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2019

Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. 

View Details

Acute Heart Failure | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of heart failure (HF) comprises epidemiological estimates of key patient populatio...

View Details